Is JNJ or KLRA more undervalued in 2026?

CirclFi compares Johnson & Johnson (JNJ) and Kailera Therapeutics, Inc. (KLRA) using 13 institutional-grade valuation models. JNJ has a Quality of Company score of 9.7/10 while KLRA scores 1.7/10.

Which is a better buy — JNJ or KLRA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do JNJ and KLRA valuations compare?

JNJ at $225.33 and KLRA at $22.94 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

JNJ vs KLRA Valuation Comparison 2026 — Intrinsic Value Analysis

JNJ

Pharmaceutical Preparations

Johnson & Johnson

Quality

9.7

out of 10

Value Trap

SAFE

Price

$225.33

Last close

Models

12/13

Active

KLRA

Pharmaceutical Preparations

Kailera Therapeutics, Inc.

Quality

1.7

out of 10

Value Trap

—

Price

$22.94

Last close

Models

5/13

Active

Model-by-Model Comparison

Model	Type	JNJ Fair Value	JNJ Upside	KLRA Fair Value	KLRA Upside
Bayesian DCF	Intrinsic	$76.89	-65.9%	$5.97	-74.0%
Earnings Power Value	Intrinsic	$50.60	-77.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$92.46	-59.0%	$3.09	-86.5%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for JNJ vs KLRA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

JNJ vs KLRA — Which Stock Is More Undervalued?

JNJ scores higher with a 9.7/10 quality rating vs KLRA's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Johnson & Johnson (JNJ) and Kailera Therapeutics, Inc. (KLRA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

JNJ currently trades at $225.33 with a QOC of 9.7/10, while KLRA trades at $22.94 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).